Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Safety and tolerability of antiretrovirals during pregnancy Weinberg A; Forster-Harwood J; Davies J; McFarland EJ; Pappas J; Kinzie K; Barr E; Paul S; Salbenblatt C; Soda E; Vazquez A; Levin MJInfect Dis Obstet Gynecol 2011[]; 2011 (ä): 867674Combination antiretroviral therapy (CART) dramatically decreases mother-to-child HIV-1 transmission (MTCT), but maternal adverse events are not infrequent. A review of 117 locally followed pregnancies revealed 7 grade >/= 3 AEs possibly related to antiretrovirals, including 2 hematologic, 3 hepatic, and 2 obstetric cholestasis cases. A fetal demise was attributed to obstetric cholestasis, but no maternal deaths occurred. The drugs possibly associated with these AE were zidovudine, nelfinavir, lopinavir/ritonavir, and indinavir. AE or intolerability required discontinuation/substitution of nevirapine in 16% of the users, zidovudine in 10%, nelfinavir in 9%, lopinavir/ritonavir in 1%, but epivir and stavudine in none. In conclusion, nevirapine, zidovudine, and nelfinavir had the highest frequency of AE and/or the lowest tolerability during pregnancy. Although nevirapine and nelfinavir are infrequently used in pregnancy at present, zidovudine is included in most MTCT preventative regimens. Our data emphasize the need to revise the treatment recommendations for pregnant women to include safer and better-tolerated drugs.|Adult[MESH]|Anti-Retroviral Agents/administration & dosage/*adverse effects[MESH]|Drug Therapy, Combination/adverse effects/methods[MESH]|Female[MESH]|HIV Infections/blood/*drug therapy/prevention & control/transmission[MESH]|Humans[MESH]|Infectious Disease Transmission, Vertical/*prevention & control[MESH]|Pregnancy[MESH]|Pregnancy Complications, Infectious/blood/*drug therapy/virology[MESH]|Retrospective Studies[MESH]|Risk Factors[MESH] |